Press Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Keywords Go Advanced Search Search Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard Aug 10, 2022 Evofem Biosciences to Host Investor Call on Thursday, August 11, 2022 Aug 4, 2022 Evofem Biosciences Announces Strong Second Quarter 2022 Financial Results and Affirms 2022 Guidance Aug 3, 2022 Evofem Biosciences Strengthens Board of Directors Aug 1, 2022 Evofem Announces Completion of Last Subject Last Visit (LSLV) in Registrational Phase 3 "EVOGUARD" Trial Evaluating Phexxi® for the Prevention of Chlamydia and Gonorrhea in Women Jul 29, 2022 Evofem Biosciences Commends Tri-Agencies for Clarifying that Contraceptives Must be Covered at No Cost to Individuals Jul 28, 2022 Evofem Biosciences to Report Second Quarter 2022 Results and Provide Corporate Update on Thursday, August 4, 2022 Jul 26, 2022 Evofem's House Rules Campaign Featuring Annie Murphy Receives Significant Industry Recognition Jul 25, 2022 Evofem Biosciences Unveils New Educational Birth Control Chart to Assist Providers in Patient Contraceptive Counseling Documents 1 Jul 22, 2022 Evofem Biosciences Applauds U.S. House of Representatives for Passing The Right to Contraception Act Jul 21, 2022 Evofem Partners with a360 Media to Support Phexxi® Prescription Growth Jul 12, 2022 Phexxi® Mechanism of Action Article Published in the Journal of Therapeutic Advances in Reproductive Health Jun 30, 2022 Evofem Strengthens Phexxi® Intellectual Property with New Composition of Matter Patent From USPTO Jun 28, 2022 Evofem Reaches Agreement with One of the Largest Pharmacy Benefit Managers in the U.S. for Access to Phexxi® Jun 2, 2022 US Food and Drug Administration Extends Phexxi® Shelf Life to Four Years May 20, 2022 Evofem Biosciences Announces Pricing of Approximately $26.6 Million Public Offering May 19, 2022 Evofem Biosciences Announces Proposed Public Offering May 10, 2022 Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Services for the Commercial Manufacturing of Phexxi® May 6, 2022 Evofem Presents Data Detailing Fewer Urinary Tract Infections in Women Using Phexxi in the Phase 3 AMPOWER Clinical Trial May 5, 2022 Evofem Biosciences Announces 1-for-15 Reverse Stock Split May 4, 2022 Evofem Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update Apr 27, 2022 Evofem Improves Phexxi® Patient Experiences Through New Agreement with VitaCare Prescription Services Apr 26, 2022 Evofem to Present New Research in Gynecological Health at the 2022 American College of Obstetricians and Gynecologists Annual Meeting Apr 25, 2022 Evofem Biosciences to Report First Quarter 2022 Results and Provide Corporate Update on Wednesday, May 4, 2022 Apr 19, 2022 Journal of Sexual Medicine Publishes Sexual Satisfaction Data Involving Phexxi® from Evofem's Phase 3 AMPOWER Clinical Trial Apr 11, 2022 Evofem Announces Karina Fedasz as Company's New Head of Business Development Show 5102550100 per page«12345678910»
